Study of the metabolic syndrome severity index as a predictive factor of a major of cardiovascular event in premenopausal women with systemic lupus erythematosus

[1]  D. Khalili,et al.  Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study , 2023, Scientific reports.

[2]  T. Ortel,et al.  Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management , 2023, BMJ.

[3]  J. Frostegård.  Systemic lupus erythematosus and cardiovascular disease , 2022, Journal of internal medicine.

[4]  C. Vargas‐De‐León,et al.  Derivation and validation of sex-specific continuous metabolic syndrome scores for the Mexican adult population , 2022, Scientific Reports.

[5]  M. Kaplan,et al.  Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus , 2022, Seminars in Immunopathology.

[6]  C. Aguilar-Salinas,et al.  Trends in the prevalence of metabolic syndrome and its components in Mexican adults, 2006-2018. , 2021, Salud publica de Mexico.

[7]  F. Vincent,et al.  Associations of metabolic syndrome in SLE , 2020, Lupus science & medicine.

[8]  D. Gladman,et al.  Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort , 2020, The Journal of Rheumatology.

[9]  D. Nikolopoulos,et al.  Cardiovascular Disease in Systemic Lupus Erythematosus: recent data on epidemiology, risk factors and prevention. , 2019, Current vascular pharmacology.

[10]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[11]  T. Subramaniam,et al.  Development of a metabolic syndrome severity score and its association with incident diabetes in an Asian population—results from a longitudinal cohort in Singapore , 2019, Endocrine.

[12]  K. Sung,et al.  Metabolic Syndrome Severity Score in Korean Adults: Analysis of the 2010–2015 Korea National Health and Nutrition Examination Survey , 2019, Journal of Korean medical science.

[13]  Yuhui Zhang,et al.  Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta‐analysis , 2017, International journal of rheumatic diseases.

[14]  I. Bruce,et al.  Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort , 2016, Lupus Science & Medicine.

[15]  D. Isenberg,et al.  Why and how should we measure disease activity and damage in lupus? , 2014, Presse medicale.

[16]  Matthew J Gurka,et al.  An examination of sex and racial/ethnic differences in the metabolic syndrome among adults: a confirmatory factor analysis and a resulting continuous severity score. , 2014, Metabolism: clinical and experimental.

[17]  S. Lekamwasam,et al.  Factors that determine body composition of female systemic lupus erythematosus (SLE) patients in Sri Lanka: a comparative study using dual-energy x-ray absorptiometry , 2013, Lupus.

[18]  J. Reveille,et al.  Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). , 2010, Rheumatology.

[19]  D. Gladman,et al.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus , 2010, Arthritis care & research.

[20]  S. Manzi,et al.  Cardiovascular risk assessment and treatment in systemic lupus erythematosus. , 2009, Best practice & research. Clinical rheumatology.

[21]  J. Reveille,et al.  Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort. , 2008, Rheumatology.

[22]  I. Bruce,et al.  Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort , 2007, Lupus.

[23]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[24]  M. Petri,et al.  Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. , 2005, Arthritis and rheumatism.

[25]  J. Reveille,et al.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. , 2004, Arthritis and rheumatism.

[26]  M. Abrahamowicz,et al.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[27]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[28]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[29]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[30]  R. Rojas,et al.  El síndrome metabólico: un concepto en evolución , 2004 .